Angiotensin II receptor binding and actions in NG108-15 cells. 1989

R C Speth, and L Mei, and H I Yamamura
Dept. VCAPP, Washington State University, Pullman 99164-6520.

NG108-15 cells were grown in culture to confluency and membranes were prepared from the cells to test for the presence of angiotensin II (Ang II) receptors using 125I-sarcosine1, isoleucine8 angiotensin II (125I-SI Ang II). These radioligand binding studies indicated a single class of binding sites with high affinity (KD = 221 +/- 54 pM) that were saturable (Bmax = 27.2 +/- 1.6 fmol/mg protein) and showed characteristic specificity (SI Ang II greater than Ang II greater than Sar1Thr8 Ang II greater than Ang III greater than Ang I greater than des Phe8 Ang II greater than des Asp1, Arg2, Val3 pentapeptide Ang II). To see if these putative receptor binding sites were associated with a functional response, the effect of Ang II on phosphatidylinositide (PtdIns) hydrolysis, expressed as inositol monophosphate (IP1) formation in intact NG108-15 cells preloaded with 3H-myoinositol, was determined. Ang II inhibited IP1 formation up to 35% below the basal rate in a dose related manner. The inhibition of PtdIns hydrolysis was prevented by pre-exposure of the cells to SI Ang II, an Ang II receptor antagonist. These results indicate that undifferentiated NG108-15 cells possess Ang II receptors that mediate a reduction in PtdIns hydrolysis.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D010716 Phosphatidylinositols Derivatives of phosphatidic acids in which the phosphoric acid is bound in ester linkage to the hexahydroxy alcohol, myo-inositol. Complete hydrolysis yields 1 mole of glycerol, phosphoric acid, myo-inositol, and 2 moles of fatty acids. Inositide Phospholipid,Inositol Phosphoglyceride,Inositol Phosphoglycerides,Inositol Phospholipid,Phosphoinositide,Phosphoinositides,PtdIns,Inositide Phospholipids,Inositol Phospholipids,Phosphatidyl Inositol,Phosphatidylinositol,Inositol, Phosphatidyl,Phosphoglyceride, Inositol,Phosphoglycerides, Inositol,Phospholipid, Inositide,Phospholipid, Inositol,Phospholipids, Inositide,Phospholipids, Inositol
D011869 Radioligand Assay Quantitative determination of receptor (binding) proteins in body fluids or tissue using radioactively labeled binding reagents (e.g., antibodies, intracellular receptors, plasma binders). Protein-Binding Radioassay,Radioreceptor Assay,Assay, Radioligand,Assay, Radioreceptor,Assays, Radioligand,Assays, Radioreceptor,Protein Binding Radioassay,Protein-Binding Radioassays,Radioassay, Protein-Binding,Radioassays, Protein-Binding,Radioligand Assays,Radioreceptor Assays
D011945 Receptors, Angiotensin Cell surface proteins that bind ANGIOTENSINS and trigger intracellular changes influencing the behavior of cells. Angiotensin Receptor,Angiotensin Receptors,Angiotensin II Receptor,Angiotensin III Receptor,Receptor, Angiotensin II,Receptor, Angiotensin III,Receptor, Angiotensin
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D005910 Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21) Glial Cell Tumors,Malignant Glioma,Mixed Glioma,Glial Cell Tumor,Glioma, Malignant,Glioma, Mixed,Gliomas,Gliomas, Malignant,Gliomas, Mixed,Malignant Gliomas,Mixed Gliomas,Tumor, Glial Cell,Tumors, Glial Cell
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

R C Speth, and L Mei, and H I Yamamura
June 1991, Hypertension (Dallas, Tex. : 1979),
R C Speth, and L Mei, and H I Yamamura
January 1991, Neuroscience,
R C Speth, and L Mei, and H I Yamamura
April 1992, The Journal of biological chemistry,
R C Speth, and L Mei, and H I Yamamura
March 1990, Biochemical and biophysical research communications,
R C Speth, and L Mei, and H I Yamamura
February 2003, The Journal of biological chemistry,
R C Speth, and L Mei, and H I Yamamura
September 1992, FEBS letters,
R C Speth, and L Mei, and H I Yamamura
January 1990, Journal of cardiovascular pharmacology,
R C Speth, and L Mei, and H I Yamamura
November 2010, Molecular and cellular neurosciences,
R C Speth, and L Mei, and H I Yamamura
October 1997, Cellular and molecular neurobiology,
Copied contents to your clipboard!